ADVERTISEMENT
Search

APhA's Initiating Buprenorphine Certificate Training Program

APhA's Initiating Buprenorphine Certificate Training Program

APhA's Initiating Buprenorphine Certificate Training Program is a comprehensive, webinar-based training program is designed to meet the Substance Abuse and Mental Health Services Administration (SAMHSA) training requirements for Medication Access and Training Expansion (MATE) Act of 2023. Pharmacists and physicians who are interested in initiating medications for opioid use disorder will learn about screening, non-pharmacologic and pharmacologic management and communication and addressing barriers related to management of pain and substance use disorders.

Pricing
  • Member Price: $49
  • Nonmember Price: $99

If your company or organization is interested in offering this program to your pharmacists or student pharmacists, please contact Chris McKerrow.


Learning Objectives & Module Details
Module 1: Principles of Proper Pain Management

At the completion of this ​Application-Based​ activity, participants will be able to:

  • Identify quantitative and qualitative strategies for comprehensive pain assessment.
  • Discuss nonpharmacologic and pharmacologic options for multi-modal pain management.
  • Describe appropriate methods to taper chronic opioid therapy as part of an interdisciplinary team.
  • Develop an effective treatment plan given a patient case scenario.
Module 2: Screening, Brief Intervention, and Interdisciplinary Collaboration in SUD

At the completion of this ​Knowledge-Based​ activity, participants will be able to:

  • Identify quantitative and qualitative strategies for comprehensive pain assessment.
  • Discuss nonpharmacologic and pharmacologic options for multi-modal pain management.
  • Describe appropriate methods to taper chronic opioid therapy as part of an interdisciplinary team.
  • Develop an effective treatment plan given a patient case scenario.
Module 3: Pharmacologic Treatment for SUD

At the completion of this ​Application-Based​ activity, participants will be able to:

  • Describe the prevalence and long-term risks of AUD and OUD.
  • Review evidence-based treatment options for AUD and OUD.
  • Discuss considerations for management of polysubstance use.
  • Construct a patient-specific pharmacotherapy plan for OUD.
Module 4: The Intersection of Mental Health Conditions and SUD

At the completion of this ​Knowledge-Based​ activity, participants will be able to:

  • Recognize the incidence of co-occurring mental health and substance use disorders.
  • Outline potential treatments and services for individuals with co-occurring mental health and substance use disorders.
Module 5: From Bystander to Advocate: Harm Reduction

At the completion of this ​Knowledge-Based​ activity, participants will be able to:

  • Describe the impact of harm reduction efforts.
  • Recognize barriers to seeking and receiving tools to promote harm reduction and recovery.
  • Practice statements that can be used to express concern for patients with addiction and promote behavior change.
  • Discuss strategies to engage patients in care related to substance use disorders.
Module 6: The Self in Shame: Healing the Wounds of Substance Use Disorders

At the completion of this ​Knowledge-Based​ activity, participants will be able to:

  • Distinguish between the following terms: healthy shame, unhealthy shame, guilt, and stigma.
  • Explain how feelings related to shame can impact the treatment of substance use disorders and recovery process.
  • Describe how pharmacists can use the principles of healthy and unhealthy shame in assisting patients who are recovering or struggling with substance use disorders.
Module 7: Addressing SDOH and Disparities in Pain Management

At the completion of this ​Knowledge-Based​ activity, participants will be able to:

  • Describe the relationship between social and economic determinants of health, risk for development of chronic pain, and risk for inadequate pain management.
  • Summarize ways that pharmacists and healthcare providers can reduce bias that contributes to health disparities in pain management.
  • Identify available tools and resources for pharmacists to address barriers to effective pain management.
Module 8: Legal Responsibilities in Buprenorphine Prescribing

At the completion of this ​Knowledge-Based​ activity, participants will be able to:

  • Summarize current legislation allowing for pharmacists’ prescriptive authority of controlled substances.
  • Identify legal requirements for prescribing buprenorphine.

How to Obtain a Certificate of Completion
  • Complete 8 self-study modules, each of which consists of a recorded webinar, an assessment, and a module evaluation.
  • Achieve a passing grade of 70% or higher on each module assessment.
  • Credit must be claimed for each module to obtain credit.
  • Participants will need to have a valid APhA (pharmacist.com) username and password, as well as a CPE Monitor account to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
  • The Certificate of Completion will be available online upon successful completion of all 8 module activities on the participant's My Training page.
  • APhA continuing pharmacy education policy provides you with two opportunities to successfully complete a continuing pharmacy education assessment. Please note that you will not be permitted to submit an assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This is intended to maintain the integrity of the CPE activity and the assessment.
Accreditation Information

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. APhA's Initiating Buprenorphine Certificate Training Program is approved for a total of 8.0 contact hours of continuing pharmacy education (CPE) credit (0.8 CEUs). The ACPE Universal Activity Numbers (UAN) for this activity are listed below.

  • Initiating Buprenorphine Certificate Training Program is approved for 8 hours (0.8 CEU) of CPE credit. ACPE UAN 0202-0000-23-399-H08-P
  • Target Audience: Pharmacists
  • Release Date: October 19, 2023
  • Expiration Date: October 26, 2023 - PLEASE NOTE: NO Home Study credit granted after this date.
Technology Requirements and Tips

Computer and Internet access are required to complete this activity. If you experience technical difficulties, try a different web browser.

Please be aware that if the system detects no activity for an extended amount of time while the screen is open in the interactive activity, the Next button may freeze, and you will need to Restart that activity again.

The recommendation is that if you cannot complete the activity within one sitting and need to step away, close the activity so that your place is bookmarked.

If you continue to experience difficulties, please reach out to education@aphanet.org with the name of course, details of your experience, which web browser(s) used and if possible, screenshots.


Faculty

Michael C. Barnes, Esq.

Principal Attorney
Sequel Legal
Washington, DC

Disclosure: Author has nothing to disclose

Abigail Cotton, MPH, CPH

Assistant Director, Clinical Coordinating Center – LITES Network
University of Pittsburgh
Pittsburgh, PA

Disclosure: Author has nothing to disclose

Jeffrey Gold, PharmD, BCPP

Mental Health Clinical Pharmacy Specialist
Denver VA Medical Center
Aurora, CO

Disclosure: Author has nothing to disclose

Anita Jacobson, PharmD

Clinical Professor
University of Rhode Island
Kingston, RI

Disclosure: Author has nothing to disclose

Emily E. Leppien, PharmD, BCPS, BCPP

Clinical Associate Professor
Binghamton University School of Pharmacy and Pharmaceutical Sciences
Binghamton, NY

Disclosure: Author has nothing to disclose

Jake Nichols, PharmD, MBA

Co-Founder & Chief Medical Officer
Ignite BioMedical
Boston, MA

Disclosure: At the time of content development, author was not employed at Ignite BioMedical

Laura Palombi, PharmD, MPH, MAT

Professor
University of Minnesota College of Pharmacy
Duluth, MN

Disclosure: Author has nothing to disclose

Haley Pals, PharmD, BCPP

Psychiatric Clinical Pharmacist
Tomah VA Medical Center
Tomah, WI

Disclosure: Author has nothing to disclose

Development

Initiating Buprenorphine Certificate Training Program was developed by the American Pharmacists Association. Copyright © 2023 by the American Pharmacists Association.
APhA's Education staff involved in the review of this content declare no conflict of interest or financial interest in any product or service mentioned, including grants, employment, gifts, stock holdings, and honoraria. For a full listing of APhA Staff Disclosures, please see the APhA Disclosure Statement webpage at APhA Staff Disclosures.
ADVERTISEMENT